{"url_path":"/sec/inbp/8-k/2026-07-02/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **  **FINANCIAL STATEMENTS AND EXHIBITS**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1016504/0001437749-26-022415-index.html","accession_number":"0001437749-26-022415","cik":"0001016504","ticker":"INBP","issuer_name":"INTEGRATED BIOPHARMA INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1016504/0001437749-26-022415-index.html","primary_entity_key":"0001016504","primary_entity_name":"INTEGRATED BIOPHARMA INC"},"word_count":211,"has_tables":true,"body_markdown":"**ITEM 9.01.**  **FINANCIAL STATEMENTS AND EXHIBITS**\n\n \n\n(d)           Exhibits.\n\n \n\n \n\n10.1\n \n[Amendment to ](ex_983423.htm)[Loan Documents dated as of April 15, 2025 by and between Integrated BioPharma, Inc. and Manhattan Drug Company, Inc. and PNC Bank, National Association](ex_803849.htm)\n\n10.2\n \n[Convertible Line of Credit Note (Daily SOFR) dated June 30, 2026 by Integrated BioPharma, Inc. and Manhattan Drug Company, Inc. and payable to the order of PNC Bank, National Association](ex_983424.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n \n\n \n\n-1-\n\n[Table of Contents](#toc)\n\n \n\n**EXHIBIT INDEX**\n\n \n\n \n\n \n\n \n \n \n\n**Exhibit**\n\n \n\n**Description**\n\n \n \n\n10.1\n \n[Amendment to Loan Documents dated as of April 15, 2025 by and between Integrated BioPharma, Inc. and Manhattan Drug Company, Inc. and PNC Bank, National Association](ex_983423.htm)\n\n10.2\n \n[Convertible Line of Credit Note (Daily SOFR) dated June 30, 2026 by Integrated BioPharma, Inc. and Manhattan Drug Company, Inc. and payable to PNC Bank, National Association](ex_983424.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n-2-\n\n[Table of Contents](#toc)\n\n \n\n**SIGNATURE**\n\n \n\n \n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\n**INTEGRATED BIOPHARMA, INC.**\n\n \n \n\nDate: July 2, 2026\n\nBy:     */s/ Dina L Masi*\n\n \n\n          Dina L Masi\n\n \n\n          Chief Financial Officer\n\n \n\n \n\n \n\n \n\n \n\n-3-\n\n[Table of Contents](#toc)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n-3-"}